SNDX - Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference

PR Newswire

WALTHAM, Mass. , Jan. 7, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison , M.D., Chief Executive Officer of Syndax, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 08:15 a.m. ET .

A live webcast of the presentation can be accessed from the Investor section of the Company's website at www.syndax.com , where a replay of the event will also be available for a limited time.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn .

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902

Media Contact
Benjamin Kolinski
benjamin.kolinski@gcihealth.com
Tel 862.368.4464

SNDX-G

SOURCE Syndax Pharmaceuticals, Inc.